Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals. Financial performance showed a decrease in revenues and a net loss, but optimistic guidance and strategic initiatives like Elfabrio's rollout and PRX-115 development are promising. The Q&A highlighted potential market opportunities and competitive advantages, yet management's lack of specifics on timelines and targets raises uncertainties. The positive milestone payment and strategic focus on high unmet needs balance the negative financials and manufacturing issues. Overall, the sentiment is neutral due to balanced positives and negatives, with no market cap data to assess potential volatility.
Key Financial Performance
Revenues from selling goods $51.8 million, a modest decrease compared to 2024. This was driven by change of quantities sold to Chiesi's inventory and the change in average net selling price of the drug product due to increased commercial patients in Europe.
Revenues from license and R&D services $0.9 million, an increase mainly related to agreements with Chiesi.
Cost of goods sold $27 million, reflecting higher sales volume to Pfizer and Fiocruz, partially offset by lower sales to Chiesi.
R&D expenses $19.6 million, rising 51% year-over-year. This increase was driven mainly by spending on the PRX-115 RELEASE study.
SG&A expenses $11.7 million, a slight decline mainly due to lower share-based compensation expenses.
Financial expenses Net expense of $0.1 million, due largely to foreign exchange effects, partially offset by lower interest expenses following the full repayment of secured convertible notes in 2024.
Income tax expense $1 million, mainly related to U.S. tax regulations governing global intangible low-taxed income.
Net loss $6.6 million compared to a net income of $2.9 million in 2024. The loss reflects increased investment in the clinical pipeline.
Cash, cash equivalents, and short-term bank deposits $30.3 million as of December 31, 2025. The $25 million milestone payment triggered by the European Commission approval supports a projected cash balance of approximately $50 million by early April 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Approval of new dosing regimen for Elfabrio: The European Commission approved a 2 mg/kg every 4-week dosing regimen for adults with Fabry disease, enhancing treatment options and long-term management.
Pipeline advancement: PRX-115 Phase II trial (RELEASE study) is enrolling patients, with top-line results expected in the second half of 2027. PRX-119 and RNA-based collaborations are also progressing.
Market positioning of Elfabrio: The new dosing regimen approval strengthens Elfabrio's competitive position in the EU. The Fabry market is projected to reach $3.4 billion by 2030.
Revenue growth and projections: 2026 revenue is projected to grow by over 50%, reaching $78-$83 million, driven by Chiesi's contributions and milestone payments.
Financial flexibility: A $25 million milestone payment from Chiesi boosts the projected cash balance to $50 million by early April 2026, supporting strategic initiatives.
Shift towards Chiesi: Revenues are increasingly driven by Chiesi, with a high-margin contribution expected to dominate the revenue mix in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue dependency on Chiesi: The company increasingly relies on Chiesi for long-term revenue, with a projected shift in revenue mix towards Chiesi over time. This dependency could pose risks if Chiesi faces operational or market challenges.
R&D expense increase: R&D expenses rose by 51% year-over-year, driven by investments in the PRX-115 RELEASE study and renal programs. Continued increases in R&D spending could strain financial resources if revenue growth does not keep pace.
Net loss in 2025: The company recorded a net loss of $6.6 million in 2025, compared to a net income of $2.9 million in 2024. This reflects increased investment in clinical pipelines and could impact financial stability if losses persist.
Revenue fluctuations: Revenues from partners may fluctuate quarter-by-quarter due to inventory management and purchasing patterns, creating potential unpredictability in financial performance.
Manufacturing issues at Pfizer: Increased purchases of Elelyso by Pfizer were driven by unexpected manufacturing issues on Pfizer's end. Such issues could disrupt supply chains and impact revenue stability.
Regulatory milestone dependency: The $25 million milestone payment from Chiesi, triggered by European Commission approval, significantly strengthens financial flexibility. However, reliance on such milestone payments introduces risk if future regulatory milestones are delayed or not achieved.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Projected Cash Balance: Protalix anticipates a cash balance of approximately $50 million by early April 2026, supported by a $25 million milestone payment from Chiesi.
Revenue Guidance for 2026: Total revenues are expected to range from $78 million to $83 million, including the $25 million milestone payment. Revenues from Chiesi are projected to be $33 million to $35 million, representing growth of over 50%, while revenues from Elelyso are expected to be $20 million to $23 million.
Market Trends: The Fabry disease market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile strengthening its competitive position.
Pipeline Development: The Phase II RELEASE study for PRX-115 is enrolling patients, with top-line results anticipated in the second half of 2027. PRX-115 is positioned as a potential best-in-class therapy for uncontrolled gout. Additionally, the company is expanding its rare renal pipeline with PRX-119 and other RNA-based collaborations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the additional marketing and promotional initiatives planned by Chiesi for Elfabrio in the United States for the remainder of 2026?
A:Chiesi has been focusing on promotional activities, including targeting naive and switch patients in the U.S. They have been conducting promotions with patients that are not permissible in Europe. These efforts have shown positive results in increasing patient uptake.
Q:How will the recent approval of the less frequent dosing regimen in Europe affect sales trajectory, and what is the timing for potential approval in the United States?
A:The less frequent dosing regimen (once in 4 weeks) is expected to reduce the burden on patients and provide a competitive edge in Europe. However, it will take time for all European countries to get reimbursement approvals. Regarding the U.S., the approval in Europe may accelerate the process, but it is too early to provide a definitive timeline.
Q:How might PRX-115 be positioned in the gout market if approved, and what are its competitive advantages?
A:PRX-115 is being studied with multiple dosing regimens, including once in 4, 6, and 8 weeks with methotrexate, and one month without methotrexate. These regimens could offer significant differentiation in terms of convenience and potentially favorable immunogenicity. The gout market is expected to grow to over $2 billion by 2031-2032, and PRX-115 could capture a significant market share if it proves to be a differentiated asset.
Q:Which rare renal conditions will PRX-119 target, and what are the commercial opportunities?
A:The specific renal conditions and mechanism of action for PRX-119 are still under investigation. The company plans to provide updates by the end of Q2 after completing additional experiments. They aim to target high unmet need renal indications with significant potential for patient benefit.
Q:What is the estimated timeline for the rollout of Elfabrio's 4-week dosing in Europe, and will there be a physician education effort?
A:The rollout timeline varies by country in Europe due to different regulatory and reimbursement processes. Some markets will see availability soon, while others may take a few months. The impact is expected to start in the second half of 2026 and grow in 2027. Chiesi is actively engaging with treating physicians and stakeholders to support the rollout.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the specific timeline for U.S. approval of Elfabrio's less frequent dosing regimen, stating it was too early to comment. Similarly, they did not provide details on the specific renal conditions targeted by PRX-119, asking for more time to complete experiments and analysis before sharing updates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BioTherapeutics Full
Chiesi RD
Chiesi Revenues
Chiesi United
Chiesi achievement
Chiesi effort
Chiesi majority
Chiesi margin
Chiesi milestone
Dror
Elelyso
European Commission
Full Financial
Gilad
Pfizer
RELEASE study
Results Update
Update Conference
adult disease
approval week
cash balance
expense
income loss
investment
milligram
mix Chiesi
outlook
partner Chiesi
position
potential
profile
revenue Chiesi
therapy
week regimen
PLX Transcript
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call presented mixed signals. Financial performance showed a decrease in revenues and a net loss, but optimistic guidance and strategic initiatives like Elfabrio's rollout and PRX-115 development are promising. The Q&A highlighted potential market opportunities and competitive advantages, yet management's lack of specifics on timelines and targets raises uncertainties. The positive milestone payment and strategic focus on high unmet needs balance the negative financials and manufacturing issues. Overall, the sentiment is neutral due to balanced positives and negatives, with no market cap data to assess potential volatility.
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals mixed signals: increased R&D expenses and net loss improvement are positive, but unclear responses on revenue guidance and cash burn are concerning. The positive outlook for PRX-115's market potential and Elfabrio's potential EMA approval are offset by limited visibility on financial metrics. The Q&A section highlights uncertainties, with management's evasive answers potentially dampening investor confidence. Overall, the stock is likely to remain stable, resulting in a neutral sentiment.
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed picture: increased revenues and a return to profitability are positive, but higher R&D expenses and unclear management responses in the Q&A raise concerns. While strong sales to Chiesi and improved net income are encouraging, the lack of guidance on key strategic areas and potential financial strain from increased R&D costs suggest a cautious outlook. The absence of a new partnership announcement or significant guidance changes also tempers enthusiasm, leading to a neutral sentiment prediction.
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript
Unknown5-10
The earnings call reveals several concerns: missed EPS expectations, increased R&D expenses, and significant supply chain costs. While revenue from selling goods increased, the cost of goods sold rose dramatically, indicating potential operational inefficiencies. The Q&A session highlighted uncertainties in regulatory outcomes and vague management responses, further undermining confidence. Despite some positive revenue growth, the lack of a share repurchase program and financial instability suggest a negative outlook for the stock price.
PLX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
